Jonathan A. Leon Sells 5,000 Shares of Owens & Minor, Inc. (NYSE:OMI) Stock

Owens & Minor, Inc. (NYSE:OMI) SVP Jonathan A. Leon sold 5,000 shares of Owens & Minor stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $24.84, for a total value of $124,200.00. Following the completion of the transaction, the senior vice president now directly owns 84,673 shares in the company, valued at $2,103,277.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Owens & Minor Price Performance

Shares of OMI stock opened at $24.74 on Thursday. The stock’s fifty day simple moving average is $25.11 and its 200 day simple moving average is $21.03. The company has a debt-to-equity ratio of 2.05, a current ratio of 1.11 and a quick ratio of 0.52. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -45.81, a P/E/G ratio of 0.77 and a beta of 0.43. Owens & Minor, Inc. has a one year low of $13.34 and a one year high of $28.35.

Owens & Minor (NYSE:OMI) last announced its quarterly earnings results on Tuesday, February 20th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. The business had revenue of $2.66 billion for the quarter, compared to analyst estimates of $2.67 billion. Owens & Minor had a positive return on equity of 11.62% and a negative net margin of 0.40%. Owens & Minor’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 EPS. On average, analysts expect that Owens & Minor, Inc. will post 1.54 earnings per share for the current fiscal year.

Institutional Trading of Owens & Minor

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its stake in Owens & Minor by 52.1% in the 1st quarter. GAMMA Investing LLC now owns 1,644 shares of the company’s stock valued at $46,000 after buying an additional 563 shares in the last quarter. Rhumbline Advisers raised its position in Owens & Minor by 0.3% in the 3rd quarter. Rhumbline Advisers now owns 247,846 shares of the company’s stock valued at $4,005,000 after purchasing an additional 660 shares during the last quarter. Quarry LP raised its position in Owens & Minor by 38.8% in the 4th quarter. Quarry LP now owns 2,573 shares of the company’s stock valued at $50,000 after purchasing an additional 719 shares during the last quarter. Riverview Trust Co bought a new position in Owens & Minor in the 1st quarter valued at $25,000. Finally, CWM LLC raised its position in Owens & Minor by 6.5% in the 3rd quarter. CWM LLC now owns 15,707 shares of the company’s stock valued at $254,000 after purchasing an additional 952 shares during the last quarter. Institutional investors and hedge funds own 98.04% of the company’s stock.

Analyst Upgrades and Downgrades

OMI has been the topic of several recent analyst reports. SVB Leerink initiated coverage on Owens & Minor in a research report on Monday, February 26th. They issued a “market perform” rating and a $24.00 price target on the stock. Citigroup lifted their price target on Owens & Minor from $23.00 to $24.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 21st. StockNews.com raised Owens & Minor from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Barclays lifted their price objective on Owens & Minor from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 21st. Finally, TheStreet raised Owens & Minor from a “d+” rating to a “c-” rating in a report on Monday, March 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Owens & Minor currently has an average rating of “Hold” and an average target price of $23.29.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.